万泰生物：九价人乳头瘤病毒疫苗(大肠埃希菌)首次获得批签发证明

Core Viewpoint - Wantai Biological Pharmacy (603392.SH) announced that its subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received the "Biological Product Batch Release Certificate" for its nine-valent human papillomavirus (HPV) vaccine, marking its official market launch [1] Group 1 - The nine-valent HPV vaccine will enrich and optimize the company's product portfolio [1] - The product launch is expected to create new revenue and profit growth points for the company [1] - This development will enhance the company's profitability and market competitiveness, strengthening its market position [1]